Skyphar Pharmaceutical (Opc) Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth -6.90%
- Ebitda 88.64%
- Net Worth -94.56%
- Total Assets -94.61%
About Skyphar Pharmaceutical (Opc)
Skyphar Pharmaceutical (Opc) Private Limited (SPOPL) is a Company incorporated in India on 21 June 2019 (Five years and eight months 7 days old ). Its registered office is in Chandigarh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Gurucharan Dash serves as a director at the Company.
Company Details
- Location
Chandigarh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909CH2019OPC042590
- Company No.
042590
- Incorporation Date
21 Jun 2019
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
What products or services does Skyphar Pharmaceutical (Opc) Private Limited offer?
Skyphar Pharmaceutical (Opc) Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Multivitamin Syrup & Drops, Pharma & Bioanalytical Services, PCD Pharma Franchise, Common Disease Medicines, Pharmaceutical Medicine, Digestive System Drugs & Medicines, Digestive Drugs, Antacid Drugs.
Who are the key members and board of directors at Skyphar Pharmaceutical (Opc)?
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gurucharan Dash  | Director | 21-Jun-2019 | Current |
Financial Performance of Skyphar Pharmaceutical (Opc).
Skyphar Pharmaceutical (Opc) Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a slight decrease in profitability, with a 6.9% decrease in profit. The company's net worth observed a substantial decline by a decrease of 94.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Skyphar Pharmaceutical (Opc)?
Unlock access to Skyphar Pharmaceutical (Opc)'s control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Skyphar Pharmaceutical (Opc)?
Unlock and access historical data on people associated with Skyphar Pharmaceutical (Opc), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Skyphar Pharmaceutical (Opc), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Skyphar Pharmaceutical (Opc)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.